Home > Insider Trading > Filing (0001415889-25-003665)

Filing Details

Accession Number:: 0001415889-25-003665
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-11 19:51:08
Reporting Period:: 2025-02-07

Accepted Time:: 2025-02-11 19:51:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348911	Kalvista Pharmaceuticals Inc.	KALV	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1615979	Y Bong Koh	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1698082	P Nimish Shah	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1738048	Venrock Healthcare Capital Partners Iii, L.p.	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	No	No
1738053	Vhcp Management Iii, Llc	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1750761	Vhcp Co-Investment Holdings Iii, Llc	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1808512	Venrock Healthcare Capital Partners Eg, L.p.	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No
1808518	Vhcp Management Eg, Llc	C/O Venrock 7 Bryant Park, 23Rd Floor New York NY 10018	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-02-07	73,649	$9.29	5,086,445	No	4	P	Indirect	By Funds
Common Stock	Acquisiton	2025-02-10	4,137	$9.14	5,090,582	No	4	P	Indirect	By Funds
Common Stock	Acquisiton	2025-02-11	26,703	$9.18	5,117,285	No	4	P	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Funds
No	4	P	Indirect	By Funds
No	4	P	Indirect	By Funds

Footnotes

The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.15 to $9.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Consists of (i) 1,104,278 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,465 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,871,702 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.11 to $9.17 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Consists of (i) 1,104,993 shares held by VHCP3; (ii) 110,536 shares held by VHCP Co-3; and (iii) 3,875,053 shares held by VHCP EG.
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.07 to $9.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Consists of (i) 1,109,607 shares held by VHCP3; (ii) 110,998 shares held by VHCP Co-3; and (iii) 3,896,680 shares held by VHCP EG.